


# ORPHAN DRUG REPORT 2022

## Orphan drug sales growth outpace the wider market



The orphan drug market is growing more than twice as fast as the non-orphan market



**20%**

Prescription drug Sales from orphan drugs 2026

**12%**

CAGR for orphan drugs 2021 - 2026


**50%+**

**FDA**

Over half FDA's new drug approvals for orphan or rare diseases / 2021

## Big pharma is increasingly reliant on orphans

9 of the top-10 best-selling orphan drugs will be marketed or co-marketed by big pharma / 2026



*Johnson's*  
BIG PHARMA SALES

**40%**

from orphan drugs 2026

**7 OTHER**  
BIG PHARMA SALES

**20%**

## Orphans out-size mass market drugs

Two of the top selling drugs in the world.

\$13 BIL

AbbVie/J&J's (CLL) drug Imbruvica, a BTK inhibitor

\$12,74 BIL

BMS/Pfizer's mass-market blood thinner, Eliquis

\$12,8 BIL

Sanofi's anti-inflammatory Dupixent

### ORPHANS MATCH EXPECTED MASS MARKET DRUGS SALES 2026



\$10 BIL

Number 2 orphan Darzalex (J&J) for multiple myeloma


\$9,53 BIL

Novo Nordisk's diabetes best-seller Ozempic

\$8,77 BIL

AbbVie's rheumatoid arthritis drug Rinvoq


## Orphan drugs face growing competition



- Imbruvica
- Darzalex
- Venclexta
- Calquence
- Jakafi

5 blood cancer drugs account for about half of combined sales from top ten orphans in 2026

## Regulators are tightening the screws



Calls to reform orphan drug legislation and temper high prices continue.